BioSpace News Archive

TriSalus Life Sciences®, Inc. (“TriSalus” or the “company”) today announced that it has expanded the reach of its ongoing Pressure-Enabled Regional Immuno-Oncology™ (“PERIO™-01” and “PERIO™-02”) clinical program.

Chimeron Bio announced today that Antonin (Tony) de Fougerolles had been appointed as the newest member of its Board of Directors.

Arch Biopartners Inc., announced that the Company has arranged a shares for debt transaction to settle an aggregate of $201,459 in interest accrued up to September 30, 2022 on all five of the deferred convertible notes outstanding and disclosed in the Company’s financial statements.

UBC, a biopharmaceutical leader providing integrated clinical, safety, and commercialization services, announced that Nathan Thompson has joined UBC and, effective January 2, 2023, will assume the role of Chief Information Officer.

Rx.Health, the leading evidence-based automated care coordination platform, has announced a partnership with Wise Therapeutics, a leading provider of game-based digital therapeutics for mental health.

G360, the parent company of both Gravity Diagnostics and Gravity+, has promoted Dr. JP Canner, Ph.D. to serve as the company’s Chief Scientific Officer.

Partner Therapeutics, Inc. (PTx) announced publication of a single institution retrospective cohort review of 15 patients with pediatric malignancies and invasive fungal diseases that were refractory to antifungal therapy and treated adjunctively with Leukine (sargramostim; yeast-derived, glycosylated recombinant human granulocyte-macrophage colony-stimulating factor [rhu GM-CSF]).

Atara Biotherapeutics, Inc., a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, reported the grant of inducement awards to Ricardo Fonseca, its new Vice President, Operations.

AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options and improving quality of life for patients, today announced that it will report financial results for the second quarter of fiscal year 2023 before the market open on Thursday, January 5, 2023.

Guardant Health, Inc., a leading precision oncology company, announced positive results from ECLIPSE, an over 20,000 patient registrational study evaluating the performance of its blood test for detecting colorectal cancer in average-risk adults.